Author:
Sepehrinia Matin,Homayounfar Reza,Farjam Mojtaba
Abstract
AbstractCardiovascular disease (CVD) is the leading cause of mortality globally. Low-density lipoprotein (LDL) plays an important role in CVD pathophysiology. Research has shown the safety and efficacy of keeping LDL at very low levels for CVD prevention. Therefore, experts recommend intense LDL-lowering approaches starting at young ages, promoting the mantras “the lower, the better” and “the earlier, the better.” This commentary discusses the challenges regarding applying aggressive LDL-lowering approaches in the general population, including pharmacological efficacy and side effects, the cost-effectiveness of interventions, and patient adherence to treatment regimens.
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Mensah GA, Fuster V, Murray CJ, Roth GA. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82(25):2350–473.
2. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2019;140(11):e596–646.
3. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Reviews Cardiol. 2021;18(10):689–700.
4. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.
5. Nakano E, Harada T, Akashi K, Ishizu T, Seo Y, Aonuma K. Impacts of aggressive treatment with statin on cardiovascular events among patients whose LDL-cholesterol concentration within normal range: results from icas registry. Eur Heart J. 2013;34(suppl1):P2275.